Terumo Corp. (TRUMF)
14.67
-0.35
(-2.32%)
USD |
OTCM |
Dec 09, 15:31
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 21.64B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -22.23% |
| Valuation | |
| PE Ratio | 24.61 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.040 |
| Price to Book Value | 2.223 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.0987 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.1112 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 48.12% |
Profile
| Terumo Corp. engages in the manufacture and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan. |
| URL | https://www.terumo.co.jp |
| Investor Relations URL | https://www.terumo.com/investors/ |
| HQ State/Province | Tokyo |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | Feb. 12, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | Mar. 31, 2026 |
| Last Ex-Dividend Date | Sep. 30, 2025 |
Ratings
Profile
| Terumo Corp. engages in the manufacture and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan. |
| URL | https://www.terumo.co.jp |
| Investor Relations URL | https://www.terumo.com/investors/ |
| HQ State/Province | Tokyo |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | Feb. 12, 2026 (est.) |
| Last Earnings Release | Nov. 12, 2025 |
| Next Ex-Dividend Date | Mar. 31, 2026 |
| Last Ex-Dividend Date | Sep. 30, 2025 |